Evidence-based clinical practice guidelines for functional dyspepsia

Hiroto Miwa, Motoyasu Kusano, Tomiyasu Arisawa, Tadayuki Oshima, Mototsugu Kato, Takashi Joh, Hidekazu Suzuki, Kazunari Tominaga, Koji Nakada, Akihito Nagahara, Seiji Futagami, Noriaki Manabe, Akio Inui, Ken Haruma, Kazuhide Higuchi, Koji Yakabi, Michio Hongo, Naomi Uemura, Yoshikazu Kinoshita, Kentaro Sugano & 1 others Tooru Shimosegawa

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

General interest in functional gastrointestinal disorders is increasing among Japanese doctors as well as patients. This increase can be attributed to a number of factors, including recent increased interest in quality of life and advances in our understanding of the pathophysiology of gastrointestinal disease. Japan recently became the world’s first country to list “functional dyspepsia” as a disease name for national insurance billing purposes. However, recognition and understanding of functional dyspepsia (FD) remain poor, and no standard treatment strategy has yet been established. Accordingly, the Japanese Society of Gastroenterology (JSGE) developed an evidence-based clinical practice guideline for FD, consisting of five sections: concept, definition, and epidemiology; pathophysiology; diagnosis; treatment; and prognosis and complications. This article summarizes the Japanese guideline, with particular focus on the treatment section. Once a patient is diagnosed with FD, the doctor should carefully explain the pathophysiology and benign nature of this condition, establish a good doctor–patient relationship, and then provide advice for daily living (diet and lifestyle modifications, explanations, and reassurance). The proposed pharmacological treatment is divided into two steps: initial treatment including an acid inhibitory drug (H2RA or PPI) or prokinetics, (strong recommendation); second-line treatment including anxiolytics, antidepressants, and Japanese traditional medicine (weak recommendation). H. pylori eradication, strongly recommended with a high evidence level, is positioned separately from other treatment flows. Conditions that do not respond to these treatment regimens are regarded as refractory FD. Patients will be further examined for other organic disorders or will be referred to specialists using other approaches such as psychosomatic treatment.

Original languageEnglish
Pages (from-to)125-139
Number of pages15
JournalJournal of Gastroenterology
Volume50
Issue number2
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Dyspepsia
Evidence-Based Practice
Practice Guidelines
Therapeutics
Gastrointestinal Diseases
Diet Therapy
Pylorus
Anti-Anxiety Agents
Traditional Medicine
Gastroenterology
Insurance
Antidepressive Agents
Names
Life Style
Japan
Epidemiology
Quality of Life
Pharmacology
Guidelines
Acids

Keywords

  • Algorithm
  • Antianxiety drug
  • Antidepressant
  • Chronic gastritis
  • Dyspepsia
  • Guideline
  • H. pylori associated dyspepsia
  • H. pylori eradication treatment
  • Japanese traditional medicine
  • Prokinetics
  • Proton pump inhibitor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Miwa, H., Kusano, M., Arisawa, T., Oshima, T., Kato, M., Joh, T., ... Shimosegawa, T. (2015). Evidence-based clinical practice guidelines for functional dyspepsia. Journal of Gastroenterology, 50(2), 125-139. https://doi.org/10.1007/s00535-014-1022-3

Evidence-based clinical practice guidelines for functional dyspepsia. / Miwa, Hiroto; Kusano, Motoyasu; Arisawa, Tomiyasu; Oshima, Tadayuki; Kato, Mototsugu; Joh, Takashi; Suzuki, Hidekazu; Tominaga, Kazunari; Nakada, Koji; Nagahara, Akihito; Futagami, Seiji; Manabe, Noriaki; Inui, Akio; Haruma, Ken; Higuchi, Kazuhide; Yakabi, Koji; Hongo, Michio; Uemura, Naomi; Kinoshita, Yoshikazu; Sugano, Kentaro; Shimosegawa, Tooru.

In: Journal of Gastroenterology, Vol. 50, No. 2, 2015, p. 125-139.

Research output: Contribution to journalArticle

Miwa, H, Kusano, M, Arisawa, T, Oshima, T, Kato, M, Joh, T, Suzuki, H, Tominaga, K, Nakada, K, Nagahara, A, Futagami, S, Manabe, N, Inui, A, Haruma, K, Higuchi, K, Yakabi, K, Hongo, M, Uemura, N, Kinoshita, Y, Sugano, K & Shimosegawa, T 2015, 'Evidence-based clinical practice guidelines for functional dyspepsia', Journal of Gastroenterology, vol. 50, no. 2, pp. 125-139. https://doi.org/10.1007/s00535-014-1022-3
Miwa, Hiroto ; Kusano, Motoyasu ; Arisawa, Tomiyasu ; Oshima, Tadayuki ; Kato, Mototsugu ; Joh, Takashi ; Suzuki, Hidekazu ; Tominaga, Kazunari ; Nakada, Koji ; Nagahara, Akihito ; Futagami, Seiji ; Manabe, Noriaki ; Inui, Akio ; Haruma, Ken ; Higuchi, Kazuhide ; Yakabi, Koji ; Hongo, Michio ; Uemura, Naomi ; Kinoshita, Yoshikazu ; Sugano, Kentaro ; Shimosegawa, Tooru. / Evidence-based clinical practice guidelines for functional dyspepsia. In: Journal of Gastroenterology. 2015 ; Vol. 50, No. 2. pp. 125-139.
@article{8ef877000715489abbb00128b9eb02aa,
title = "Evidence-based clinical practice guidelines for functional dyspepsia",
abstract = "General interest in functional gastrointestinal disorders is increasing among Japanese doctors as well as patients. This increase can be attributed to a number of factors, including recent increased interest in quality of life and advances in our understanding of the pathophysiology of gastrointestinal disease. Japan recently became the world’s first country to list “functional dyspepsia” as a disease name for national insurance billing purposes. However, recognition and understanding of functional dyspepsia (FD) remain poor, and no standard treatment strategy has yet been established. Accordingly, the Japanese Society of Gastroenterology (JSGE) developed an evidence-based clinical practice guideline for FD, consisting of five sections: concept, definition, and epidemiology; pathophysiology; diagnosis; treatment; and prognosis and complications. This article summarizes the Japanese guideline, with particular focus on the treatment section. Once a patient is diagnosed with FD, the doctor should carefully explain the pathophysiology and benign nature of this condition, establish a good doctor–patient relationship, and then provide advice for daily living (diet and lifestyle modifications, explanations, and reassurance). The proposed pharmacological treatment is divided into two steps: initial treatment including an acid inhibitory drug (H2RA or PPI) or prokinetics, (strong recommendation); second-line treatment including anxiolytics, antidepressants, and Japanese traditional medicine (weak recommendation). H. pylori eradication, strongly recommended with a high evidence level, is positioned separately from other treatment flows. Conditions that do not respond to these treatment regimens are regarded as refractory FD. Patients will be further examined for other organic disorders or will be referred to specialists using other approaches such as psychosomatic treatment.",
keywords = "Algorithm, Antianxiety drug, Antidepressant, Chronic gastritis, Dyspepsia, Guideline, H. pylori associated dyspepsia, H. pylori eradication treatment, Japanese traditional medicine, Prokinetics, Proton pump inhibitor",
author = "Hiroto Miwa and Motoyasu Kusano and Tomiyasu Arisawa and Tadayuki Oshima and Mototsugu Kato and Takashi Joh and Hidekazu Suzuki and Kazunari Tominaga and Koji Nakada and Akihito Nagahara and Seiji Futagami and Noriaki Manabe and Akio Inui and Ken Haruma and Kazuhide Higuchi and Koji Yakabi and Michio Hongo and Naomi Uemura and Yoshikazu Kinoshita and Kentaro Sugano and Tooru Shimosegawa",
year = "2015",
doi = "10.1007/s00535-014-1022-3",
language = "English",
volume = "50",
pages = "125--139",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Evidence-based clinical practice guidelines for functional dyspepsia

AU - Miwa, Hiroto

AU - Kusano, Motoyasu

AU - Arisawa, Tomiyasu

AU - Oshima, Tadayuki

AU - Kato, Mototsugu

AU - Joh, Takashi

AU - Suzuki, Hidekazu

AU - Tominaga, Kazunari

AU - Nakada, Koji

AU - Nagahara, Akihito

AU - Futagami, Seiji

AU - Manabe, Noriaki

AU - Inui, Akio

AU - Haruma, Ken

AU - Higuchi, Kazuhide

AU - Yakabi, Koji

AU - Hongo, Michio

AU - Uemura, Naomi

AU - Kinoshita, Yoshikazu

AU - Sugano, Kentaro

AU - Shimosegawa, Tooru

PY - 2015

Y1 - 2015

N2 - General interest in functional gastrointestinal disorders is increasing among Japanese doctors as well as patients. This increase can be attributed to a number of factors, including recent increased interest in quality of life and advances in our understanding of the pathophysiology of gastrointestinal disease. Japan recently became the world’s first country to list “functional dyspepsia” as a disease name for national insurance billing purposes. However, recognition and understanding of functional dyspepsia (FD) remain poor, and no standard treatment strategy has yet been established. Accordingly, the Japanese Society of Gastroenterology (JSGE) developed an evidence-based clinical practice guideline for FD, consisting of five sections: concept, definition, and epidemiology; pathophysiology; diagnosis; treatment; and prognosis and complications. This article summarizes the Japanese guideline, with particular focus on the treatment section. Once a patient is diagnosed with FD, the doctor should carefully explain the pathophysiology and benign nature of this condition, establish a good doctor–patient relationship, and then provide advice for daily living (diet and lifestyle modifications, explanations, and reassurance). The proposed pharmacological treatment is divided into two steps: initial treatment including an acid inhibitory drug (H2RA or PPI) or prokinetics, (strong recommendation); second-line treatment including anxiolytics, antidepressants, and Japanese traditional medicine (weak recommendation). H. pylori eradication, strongly recommended with a high evidence level, is positioned separately from other treatment flows. Conditions that do not respond to these treatment regimens are regarded as refractory FD. Patients will be further examined for other organic disorders or will be referred to specialists using other approaches such as psychosomatic treatment.

AB - General interest in functional gastrointestinal disorders is increasing among Japanese doctors as well as patients. This increase can be attributed to a number of factors, including recent increased interest in quality of life and advances in our understanding of the pathophysiology of gastrointestinal disease. Japan recently became the world’s first country to list “functional dyspepsia” as a disease name for national insurance billing purposes. However, recognition and understanding of functional dyspepsia (FD) remain poor, and no standard treatment strategy has yet been established. Accordingly, the Japanese Society of Gastroenterology (JSGE) developed an evidence-based clinical practice guideline for FD, consisting of five sections: concept, definition, and epidemiology; pathophysiology; diagnosis; treatment; and prognosis and complications. This article summarizes the Japanese guideline, with particular focus on the treatment section. Once a patient is diagnosed with FD, the doctor should carefully explain the pathophysiology and benign nature of this condition, establish a good doctor–patient relationship, and then provide advice for daily living (diet and lifestyle modifications, explanations, and reassurance). The proposed pharmacological treatment is divided into two steps: initial treatment including an acid inhibitory drug (H2RA or PPI) or prokinetics, (strong recommendation); second-line treatment including anxiolytics, antidepressants, and Japanese traditional medicine (weak recommendation). H. pylori eradication, strongly recommended with a high evidence level, is positioned separately from other treatment flows. Conditions that do not respond to these treatment regimens are regarded as refractory FD. Patients will be further examined for other organic disorders or will be referred to specialists using other approaches such as psychosomatic treatment.

KW - Algorithm

KW - Antianxiety drug

KW - Antidepressant

KW - Chronic gastritis

KW - Dyspepsia

KW - Guideline

KW - H. pylori associated dyspepsia

KW - H. pylori eradication treatment

KW - Japanese traditional medicine

KW - Prokinetics

KW - Proton pump inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84925464643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925464643&partnerID=8YFLogxK

U2 - 10.1007/s00535-014-1022-3

DO - 10.1007/s00535-014-1022-3

M3 - Article

VL - 50

SP - 125

EP - 139

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 2

ER -